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OBJECTIVES We sought to evaluate clinical restenosis in a large population of patients who had undergone
coronary stent placement.
BACKGROUND One-year success after coronary stenting is limited mainly by restenosis of and requirement
for repeat revascularization of the treated lesion.
METHODS We studied 6,186 patients (6,219 lesions) pooled from several recently completed coronary
stent trials. Clinical restenosis was defined using three different definitions: target lesion
revascularization (TLR) beyond 30 days, target vessel revascularization (TVR) beyond 30
days, and target vessel failure (TVF), defined as TVR, any death, or myocardial infarction
(MI) of the target vessel territory after hospital discharge.
RESULTS By one year, 638 (12.2%) patients had TLR, 748 (14.3%) had TVR, and 848 (16.0%) had
TVF, more than two-thirds higher than the rate of these end points at six months. The
severity of angiographic restenosis (50% follow-up diameter stenosis [DS]) in 419 of 1,437
(29%) patients undergoing routine angiographic follow-up correlated directly with the
likelihood of TLR (73% vs. 26% for 70% DS compared with 60% DS). Smaller
pretreatment minimum lumen diameter (MLD), smaller final MLD, longer stent length,
diabetes mellitus, unstable angina, and hypertension were independent predictors of TLR.
Prior MI and current smoking were negative predictors.
CONCLUSIONS At one year after stenting, most clinical restenosis reflected TLR, which was predicted by the
same variables previously associated with an increased risk of angiographic restenosis. The
lower absolute rate of clinical restenosis relative to angiographic restenosis was due to
infrequent TLR in lesions with less severe (60% DS) angiographic renarrowing. (J Am
Coll Cardiol 2002;40:2082–9) © 2002 by the American College of Cardiology Foundation
Long-term clinical success after coronary stent implantation
is limited by restenosis of the index coronary lesion as well
as progression of nonstented disease at other sites. Accurate
assessment of these outcomes is critical for the evaluation of
current and future interventional devices and other therapies
designed to prevent or limit restenosis.
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Restenosis is most commonly defined by angiographic
criteria utilizing a dichotomous distinction based on 50%
diameter stenosis (DS) at the site of a previously successful
intervention. After successful coronary stent implantation, this
loss of lumen is almost entirely due to neointimal hyperplasia,
rather than elastic recoil or negative remodeling that is opera-
tive after conventional balloon angioplasty, and is essentially
complete by six months after the stent procedure (1,2).
While the study of angiographic or intravascular ultra-
sound parameters of restenosis has been useful for under-
standing biologic mechanisms of restenosis (3,4), clinical
outcomes must be regarded as the true measure of treatment
success (5). Such assessment has been limited by the
difficulty in defining clinical restenosis measures, which
correlate with the biologic response as defined by a variety of
angiographic parameters (6–8). Several potential clinical
correlates of angiographic restenosis have been studied,
ranging from a narrowly defined end point of clinically
driven repeat revascularization of the original target lesion
to the more broadly inclusive end point of target vessel
failure, which includes clinically driven revascularization of
any lesion within the target vessel, as well as any death or
myocardial infarction (MI) potentially involving the target
vessel territory. Previous studies of coronary stenting includ-
ing both angiographic and clinical restenosis outcomes have
consistently observed a significant disparity between the two
rates, with the rate of clinical restenosis about one-half of
the angiographic restenosis rate (9–11).
The aim of this study was to evaluate clinical restenosis in
a large population of coronary stent patients. We compared
the frequency of clinical restenosis during the course of
one-year follow-up and determined incremental risk as a
function of follow-up duration. Furthermore, we studied var-
ious lesion and clinical characteristics as correlates of clinical
restenosis and examined potential explanations for the disparity
in clinical and angiographic restenosis rates in a subset of
patients assigned to routine angiographic follow-up.
METHODS
Study design. Data from six major clinical trials of native
coronary artery stenting with relatively homogenous inclu-
sion criteria and study protocols were pooled for this
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analysis. The details of the study protocols and justification
for pooling have been previously reported (12). Briefly, the
population included 6,186 patients who underwent stenting
of 6,219 target vessels using the Palmaz-Schatz coronary
stent or one of six second-generation designs. The stenting
protocol for each study included routine high-pressure
postdilation with recommended balloon:artery ratios of 1.1
to 1.2:1, and aspirin plus four weeks of ticlopidine 250 mg
twice daily as the standard postprocedure antithrombotic
regimen. All of the studies utilized the same angiographic
core laboratory, and the same Clinical Events Committee
(CEC) adjudicated all clinical events.
Clinical follow-up and definitions. Clinical follow-up
was obtained at hospital discharge, and one month, six
months, and one year after the procedure. Target lesion
revascularization (TLR) was defined as any repeat percuta-
neous revascularization or surgical bypass of the original
target lesion site that occurred 30 or more days after the
index procedure and was driven by clinical findings (pres-
ence of ischemic symptoms and/or a positive functional
ischemia study), in the presence of a DS 50% as deter-
mined by the angiographic core laboratory. Even if ischemic
symptoms or a positive functional ischemia study were
absent, revascularization for a DS 70% was also consid-
ered to be clinically driven. If quantitative angiographic data
were not available or were deemed unreliable due to the
presence of diffuse disease or other technical issues, then the
presence of ischemia was considered adequate evidence for a
clinically driven indication. The target lesion was considered
to be the area covered by the stent plus a 5-mm margin
proximal and distal to the stent edges. Target lesion revas-
cularization performed earlier than 30 days after the proce-
dure was defined as related to an early procedural compli-
cation or failure and not included as clinical restenosis.
Target vessel revascularization (TVR) was defined as per-
cutaneous revascularization or bypass of the target lesion or
any segment of the epicardial coronary artery containing the
target lesion or more proximal vessels that may have been
traversed by the angioplasty guidewire during the index
procedure. Criteria for clinically driven indication and
clinical restenosis were the same as for TLR. Target vessel
failure was defined as any TVR, any death, or MI of the
target vessel territory other than that attributed to a com-
plication of the index procedure.
Angiographic follow-up. A prespecified subset of patients
from these studies was designated for routine angiographic
follow-up analysis. This subset consisted of 1,959 (31.7%)
patients with single lesion treatment, who were further
analyzed to evaluate the potential bias that routine angio-
graphic follow-up exerts on clinical decisions for repeat
revascularization as well as possible explanations for the
disparity between angiographic and clinical restenosis rates.
Angiographic restenosis was defined according to the binary
distinction of 50% DS at the time of angiographic
follow-up.
Statistical analysis. Continuous variables are presented as
medians and interquartile range. Binary variables are pre-
sented as counts and percentages. Survival estimates were
computed using Kaplan-Meier methods and compared
using the log-rank test. Predictors of TLR were analyzed
using stepwise logistic regression analysis for the population
assigned to only clinical follow-up. Patients who died or
sustained Q-wave MI before one year without prior TLR
were excluded from the models. Variables for stent model
and individual study were included in the model to assess for
association with the TLR end point. A two-sided value of p
 0.05 was required for statistical significance. The discrim-
inatory strength of multivariable associations was assessed
by the c statistic. All statistical analyses were performed
using SAS for Windows Version 6.12 (SAS Institute, Cary,
North Carolina).
RESULTS
Baseline clinical and angiographic characteristics for the
study cohort are depicted in Table 1.
Effect of follow-up duration. The effect of follow-up
duration is depicted in Figure 1, demonstrating approxi-
mately a 70% increase in each of the clinical restenosis end
points for 12-month compared with six-month follow-up
intervals.
Predictors of TLR. The significant independent predic-
tors of TLR in the cohort with only clinical follow-up are
shown in Table 2. There was no independent effect of stent
Abbreviations and Acronyms
BENESTENT  Belgian Netherlands Stent study
CEC  Clinical Events Committee
DS  diameter stenosis
MI  myocardial infarction
TLR  target lesion revascularization
TVR  target vessel revascularization
Table 1. Baseline Clinical and Lesion Characteristics
Clinical Characteristics N  6,186
Age (yrs), median (quartiles) 63 (54, 71)
Female (n, %) 2,101 (34.0)
Diabetes mellitus (n, %) 1,296 (21.0)
Hypertension (n, %) 3,569 (57.7)
Prior MI (n, %) 2,054 (33.2)
Unstable angina (n, %) 2,629 (42.5)
Cigarette smoking in past year (n, %) 1,332 (21.5)
Prior restenosis lesion (n, %) 691 (11.2)
Left anterior descending lesion (n, %) 2,549 (41.2)
Glycoprotein IIb/IIIa inhibitor (n, %) 470 (7.6)
Quantitative Angiography N  6,219
Reference diameter, median (quartiles) 2.94 (2.62, 3.29)
Diameter  2.50 mm (n, %) 1,320 (21.2)
Pretreatment MLD, median (quartiles) 0.99 (0.75, 1.28)
Lesion length, median (quartiles) 11.04 (7.99, 15.99)
Lesion length,  20 mm (n, %) 838 (13.5)
Final MLD (median [quartiles]) 2.76 (2.49, 3.06)
MI  myocardial infarction; MLD  minimum lumen diameter.
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design or individual study. Of note, left anterior descending
artery lesion treatment and prior restenosis were not signif-
icantly associated with TLR after adjustment for these
covariates. The c statistic for the model was 0.68.
Repeat TLR and follow-up DS. The mean DS at the
time the CEC adjudicated TLR was 69.1  11.9%. Figure
2 shows the cumulative frequency distribution of follow-up
DS for patients undergoing TLR. The DS was 60% for
only 22% of patients with adjudicated TLR, while 46% of
these patients had70% DS. Unadjudicated TLR included
66 (14%) patients with 50% follow-up DS, of whom 49
had reported symptoms (27 with symptoms referable to
other disease who had incidental TLR, seven with TLR
during protocol follow-up angiogram, and 15 without
documented ischemia involving the target vessel and with
clearly documented DS 50% after review of quantitative
angiography).
Clinical restenosis relative to angiographic restenosis.
Angiographic follow-up was available for 1,437 (74%) of the
1,959 lesions assigned to routine angiographic follow-up
and was performed at 202  44 days after the index
procedure. Angiographic restenosis was present in 419
(29.2%) lesions. Clinical restenosis rates (using adjudicated
or any reported event) for the patients with binary angio-
graphic restenosis are reported in Table 3, showing that only
about one-half of patients with angiographic restenosis
manifested clinical restenosis. Figure 3A displays the cumu-
lative distribution frequency of follow-up DS, and Figure
3B shows clinical restenosis rates relative to the severity of
angiographic restenosis for all patients with angiographic
binary restenosis. Nearly one-half of lesions that met criteria
for angiographic restenosis had follow-up DS 60%, and
only 22% had DS70%. The likelihood for TLR correlated
directly with severity of angiographic restenosis, being
performed in only 26% of lesions with 60% DS.
Receiver operator characteristic curves of TLR relative to
Figure 1. Clinical restenosis rates as exemplified by target lesion revascularization (TLR), target vessel revascularization (TVR), or target vessel failure
(TVF) assessed at 6, 9, or 12 months. All events adjudicated by the Clinical Events Committee, and percentages determined by Kaplan-Meier method.
Solid bar  TLR; striped bar  TVR; open bar  TVF.
Table 2. Independent Correlates of Target Lesion
Revascularization
Variables OR 95% CI
Final MLD (per mm)* 0.39 0.29–0.51
Reference diameter (per mm)* 0.48 0.40–0.59
Stent length (per 5 mm, per lesion)* 1.06 1.03–1.10
Lesion length (per 5 mm)* 1.11 1.04–1.17
Diabetes mellitus 1.49 1.16–1.92
Pretreatment MLD 0.66 0.49–0.88
Cigarette smoking (in past yr) 0.64 0.47–0.88
History of prior MI 0.70 0.54–0.90
Unstable angina 1.34 1.06–1.69
Hypertension 1.27 1.01–1.61
Variables listed in descending order of significance. *Colinear variable pairs (reference
diameter/final MLD and stent length/lesion length) were tested in separate multiva-
riable models. Other independent variables were not different between the two
models.
CI  confidence interval; MI  myocardial infarction; MLD  minimal lumen
diameter; OR  odds ratio.
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follow-up DS are shown in Figures 4A and 4B for any TLR
and adjudicated TLR, respectively.
Effect of routine angiographic follow-up. Assignment to
routine angiographic follow-up significantly increased the
rate of any TLR compared with assignment to only clinical
follow-up (17.4% vs. 12.1%, p  0.001). Adjudication by
the CEC partially corrected for this difference (13.9% vs.
11.0%, p  0.03).
DISCUSSION
Of 6,186 patients undergoing stenting of 6,219 de novo or
restenotic native coronary lesions using a variety of stent
designs, one-year clinical outcome was determined mainly
by the requirement for repeat revascularization of the
original target lesion. While definitions of clinical restenosis
that include revascularization of the entire target vessel or
attribute any death or recurrent MI in the target vessel
territory to clinical failure of the percutaneous revascular-
ization provide a more complete clinical assessment, these
events were far less frequent than TLR and increased the
absolute one-year end point rate only 2.1% and 3.8%,
respectively. While these other late events are critical to the
safety evaluation of a new device or treatment strategy, they
probably do not contribute significantly to assessments of
clinical outcomes due to restenosis per se.
Effect of follow-up duration on clinical restenosis rates.
An important finding of our study is the demonstration of
how the duration of follow-up influences the perceived rate
of clinical restenosis. Had follow-up been limited to six
months, the reported rate of TLR would have been only 7%.
While the pathologic process of restenosis occurs mostly
during the first few months and is essentially complete by six
months, our results indicate a significant delay between
those processes and clinical manifestation of restenosis as a
revascularization procedure. Longer (9 to 12 month)
follow-up for clinical restenosis end points should, thus, be
required to maximize the capture of these events. While this
lag may represent a delay in the development of symptoms
beyond the time required for completion of the biologic
restenosis process or ongoing changes in the pathophysiol-
ogy of the restenosis lesion, it more likely represents an
inherent delay caused by the time required for recognition of
symptoms and appropriate evaluation and management.
Regardless, any assessment of new devices or treatment
strategies designed to limit restenosis must consider the
time point at which clinical restenosis end points are
reported.
Disparity between angiographic restenosis and clinical
restenosis rates. The large database of coronary stent
patients including those with routine angiographic as well as
only clinical follow-up allowed for detailed evaluation of the
well-described discordance between angiographic and clin-
ical restenosis rates. The finding of clinically relevant
restenosis in only about 50% of patients with angiographic
restenosis is similar to several earlier reports (9,10,13).
Despite these numerical differences between angiographic
and clinical restenosis, however, there is compelling evi-
dence that they represent the same process through different
filters: 1) there is a clear correlation between the severity of
Figure 2. Cumulative distribution frequency of follow-up percent diameter stenosis for all patients undergoing target lesion revascularization (TLR).
Adjudicated TLR indicates the Clinical Events Committee determined the TLR was clinically driven.
Table 3. Clinical Restenosis Rates in Patients With Binary
Angiographic Restenosis
Clinical Restenosis
End Point
Any Event
N  419
Adjudicated Event
N  419
Target lesion revascularization 213 (52%) 187 (45%)
Target vessel revascularization 219 (52%) 193 (46%)
Target vessel failure 224 (53%) 198 (47%)
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angiographic restenosis and the likelihood of TLR and 2)
the same important predictors of angiographic restenosis
also predict TLR. In contrast with a dissociation of
follow-up angiographic findings and late clinical outcomes,
our results indicate that the frequent milder degrees of
angiographic restenosis do not cause sufficient limitation of
coronary blood flow to produce symptomatic ischemia and
drive the patient towards a repeat procedure. Our group has
previously reported that angiographic parameters of reste-
nosis represent a continuous process for any given lesion or
treatment device and that this process is largely dependent
on the final lumen diameter achieved (3). It is, therefore, not
Figure 3. (A) Cumulative distribution frequency of follow-up percent diameter stenosis for all patients with angiographic restenosis defined as the binary
end point (50% diameter stenosis). (B) Target lesion revascularization (TLR) rates according to severity of angiographic restenosis. Adjudicated TLR
indicates the Clinical Events Committee determined the TLR was clinically driven.
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surprising that the uniform excellent results after coronary
stenting are associated with frequent less severe angio-
graphic renarrowing.
Based on this finding, other potential cutoff values for the
dichotomous angiographic restenosis definition were tested.
Receiver operator characteristic curves demonstrate that, for
both clinically driven as well as any reported TLR, the slight
gain in specificity for cutoffs of 60% or 70% DS was
Figure 4. Receiver operator characteristic curves for target lesion revascularization (TLR) as a function of severity of angiographic restenosis (A  any
reported TLR; B  adjudicated TLR). An area under the curve approaching 1.0 represents optimal discrimination for the measure of interest (follow-up
diameter stenosis [DS]). A result in the upper left hand corner of the graph would indicate a perfect cutoff value with maximum sensitivity and specificity.
As shown in A and B, the cutoff value of 50% DS best represents this position.
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offset by much greater reductions in sensitivity. The curves
further suggest that the currently accepted definition of
50% DS provides excellent balance of sensitivity and
specificity.
Independent correlates of TLR. This pooled analysis
confirms earlier reports from BENESTENT II (11) and
adds additional power to our previous reports from ACS
Multilink Stent Clinical Equivalence Trial (ASCENT) (14)
and NIR Vascular Advanced North American Trial (NIR-
VANA) (15) (patients from ASCENT and NIRVANA are
included in the pooled analysis) that routine angiographic
follow-up significantly inflates reported rates of TLR. Of
particular note, the present study shows that this effect
remains significant even after adjudication of TLR events by
the CEC.
To avoid this potential bias, the independent correlates of
TLR were further evaluated in the patients having only
clinical follow-up. The clinical, lesion, and procedural
variables that were significantly associated with TLR were
similar to those previously reported for angiographic reste-
nosis after stent implantation, including vessel size, final
lumen diameter, lesion length, stent length, unstable angina
presentation, and the presence of diabetes mellitus (16–18).
In contrast with previous reports, we did not find that stent
design was significantly associated with TLR after adjust-
ment for these significant variables (18,19). This discrep-
ancy may be due to different assortments of available stents
between the two studies. Our finding of an association of
prior MI with lower risk for TLR more than likely repre-
sents the presence of a clinically silent, collateralized, or
nonviable territory rather than a true difference in the
severity of restenosis in these patients. We have previously
discussed the apparent paradox of a lower risk for TLR in
smokers (20).
Similar to previous studies of angiographic restenosis
(18), despite the inclusion of all clinical, lesion, and proce-
dural variables known to influence restenosis rates, the
discriminatory ability of the multivariable model is only fair
with a c statistic of 0.68. It is likely that other unmeasured
patient-specific variables account for most of this difference.
Genetic variations in platelet function (21), angiotensin-
converting enzyme activity (22,23), inflammatory response
(24,25), or alteration of one or more signal transduction
pathways (26) may be among these factors.
Study limitations. There are two important limitations of
our study. First, the patients are pooled from several
randomized clinical trials and nonrandomized registries
rather than a single clinical trial or unselected series. Even
though similar inclusion and exclusion criteria existed and
results are partially standardized by the use of the same
angiographic core laboratory and CEC, we cannot exclude
unmeasured differences in the populations or outcomes
across these studies. Secondly, because the patients and
lesions treated were highly selected as clinical trial partici-
pants and with median reference diameter approaching 3.0,
the results are not generalizable to the overall population of
patients undergoing coronary stenting. Likewise, the anal-
ysis is constrained by treatment strategies in effect at the
time of these trials and cannot assess the effect of current
strategies, such as routine use of glycoprotein IIb/IIIa
inhibitors.
Conclusions. In this selected group of patients with gen-
erally large vessel size, clinical restenosis, defined as clini-
cally indicated TLR, occurs in approximately 12% of pa-
tients by one year after the procedure, more than 70%
higher than the rate when assessed at six months. Clinical
restenosis occurs in only about one-half of patients with
angiographic restenosis and correlates directly with the
severity of angiographic renarrowing. Moreover, the clini-
cal, lesion, and procedural correlates of clinical restenosis are
similar to those of angiographic restenosis but, as in the
models for angiographic restenosis, serve as only fair pre-
dictors for individual patients. These results indicate that
evaluation of targeted antirestenosis therapies should in-
clude at least one-year follow-up for assessment of clinical
restenosis. Meanwhile, efforts should be made to optimize
modifiable procedural risk factors, while continuing to
address other potential risks that may be related to interpa-
tient differences.
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